Альфа-пвп: описание и особенности

Common street names for Alpha-PVP include 'flakka', 'gravel', and 'niff'. Routes of administration include smoking, snorting (intranasal), injection, and oral ingestion.

Alpha-PVP is not explicitly scheduled under New Zealand's Misuse of Drugs Act but is controlled via structural similarity provisions. The chemical name alpha-pyrrolidinovalerophenone is synonymous with Alpha-PVP.

Alpha-PVP imports into New Zealand have been primarily from China and Pakistan since 2012. Hypokalemia (low potassium levels) has been observed in cases of Alpha-PVP intoxication.

Common clinical symptoms include mydriasis (dilated pupils), diaphoresis (excessive sweating), and seizures.

Alpha-PVP and its metabolites can be detected in blood and urine postmortem. Alpha-PVP was originally synthesized in the 1960s but did not enter widespread illicit use until the early 2000s.

Intranasal administration leads to effects appearing within minutes, lasting approximately 3 hours. It is a molecular analogue of pyrovalerone and structurally related to MDPV (methylenedioxypyrovalerone).

Alpha-PVP (alpha-pyrrolidinovalerophenone) is a synthetic cathinone stimulant. The European Union banned Alpha-PVP in 2015.

Strong compulsive desire for re-dosing is a reported characteristic of Alpha-PVP use.

Alpha-PVP is more potent than methamphetamine in some rat self-administration studies when compared to MDPV, but less potent than methamphetamine in substitution tests. Clinical manifestations of intoxication often include tachycardia (observed in 92% of cases in one study), hypertension, and hyperthermia.

Acute effects in humans include euphoria, increased sociability, heightened libido, energy, and time distortion. In animal studies, Alpha-PVP has been found to be equally potent and effective as MDPV in terms of reinforcing effects and locomotor stimulation.

Its mechanism involves inhibiting the reuptake of dopamine (DAT) and norepinephrine (NET), leading to increased synaptic concentrations. User reports indicate a transition from initial euphoria to distress and anxiety is common.

Primary causes of death linked to Alpha-PVP use include cardiac infarction and pulmonary edema.

The drug was illegal in only a handful of US states prior to the temporary nationwide ban in 2014. The onset of effects can be subtle or delayed, which may lead to accidental overdosing due to re-dosing.

Conformational restriction of the structure (e.g., in aminotetralone derivatives) leads to lower efficacy compared to Alpha-PVP. It was placed under a temporary nationwide ban in the United States effective February 2014.

Oral administration results in effects appearing around 15 minutes post-ingestion and lasting up to 6 hours. Severe adverse effects include paranoia, agitation, hallucinations, delirium, and loss of motor control.

Visual appearance often includes small white or bluish translucent crystals with a shiny surface.